Tianfu Jincheng Laboratory(Frontier Medical Center)was opened and put into operation in Chengdu Hi-Tech Industrial Development Zone(CDHT),Sichuan province,on Nov.23.
Tianfu Jincheng Laboratory.[photo provided to China.org.cn]
Tianfu Jincheng Laboratory(Frontier Medical Center)was opened and put into operation in Chengdu Hi-Tech Industrial Development Zone(CDHT),Sichuan province,on Nov.23.
This move marks a solid step in the research of key core technologies in the field of life and health,and will provide high-level innovation platform supports for the construction of a science and technology innovation center with national influence in the Chengdu-Chongqing region in southwest China.
As one of the four key laboratories of Tianfu Laboratory,a major innovation platform project funded by Chengdu,capital of Sichuan,the newly founded medical lab is jointly established by CDHT,Sichuan University and other institutions.
Focusing on major human diseases such as major chronic diseases(malignant tumors)and oriented by clinical value,the lab aims to master the"bottleneck"technology and open up the channel between applied basic research and industrialization.It will also try and establish a leading full-life cycle pharmaceutical device creation system in the world,and realize 0-to-1 breakthrough,1-to-10 transformation and“10+N”industrialization,so as to improve the quality of people's health comprehensively.
The lab will serve the implementation of key national development strategies as well as the development of local economy.With the goal of solving the practical needs of major clinical diseases of human beings,the lab will focus on the development of key technologies in the field of human life and health that the country has not yet mastered,focusing on the 3+N research direction of original target discovery,new drug research and development,innovative medical device research and development and precision medicine.It will try to form a whole-chain pro-innovation ecology integrating research,transformation and industrialization.
By doing so,the lab intends to give full play to the advantages of scientific and technological innovation,attract global research resources to the CDHT to jointly promote technology transfer and results transformation in the region and beyond,and thereafter form an efficient open and sharing system.
According to the CDHT biological industry department,the lab will become a main platform to enhance the zone’s research and innovation capacity in medical science and relevant fields in the future,and it will work closely with the Chinese Academy of Medical Sciences,the Academy for Advanced Interdisciplinary Studies of Peking University and other research institutes to jointly hatch more R&D bases.And the lab will also collaborate with some big-name companies in related industries,including BGI and Huawei,to build more research findings transformation grids,and thus form a lab-base-grid lab-industry pro-innovation ecology.
The lab's core area is located in the Xinchuan zone,adjacent to Xinchuan TOD,with a planned investment of 10 billion yuan($1.39 billion)to form a research base covering an area of more than 1 million square meters.
CDHT is working on a list of the first batch of projects the lab will carry out.The planning of these projects follows the principles that they should be conducive to helping the lab make breakthroughs in the world,grab leading positions among its peers and strengthen and supplement relevant industry chains,with focus on meeting urgent clinical needs in practices.
It is expected that over the next three to five years the lab can be building the largest biobank in the world,the first standardized animal model database of diseases in China,the largest AI intelligent computing center with independent core database in the country,gather a group of high-end talents,and realize the listing of a batch of companies developing 10-20 innovative drugs and 15-30 innovative medical devices.The lab aims to strive to become one of the world's first-class labs in its field by 2030.
Up to now,the construction of the lab has already made some concrete progress.More than 20 innovative service platforms,including the National Precision Medicine Industry Innovation Center and the National Disease Molecular Network,have been founded in it,and 146 projects,including research on brain influence guiding neuroregulatory treatment of mental diseases,have been successfully incubated and transformed into more than 60 key projects on its various platforms.
With well-known scientists in the field as its core team,the lab has accumulated a high-level innovation research team of over 2,000 members led by academicians,such as Wei Yuquan,Zhang Xingdong,Wang Guangji and Yang Zhenglin.Collaborating scientists in the laboratory have published five papers in the world's top journals such as Science,Nature and Cell,accounting for more than 90%of the life science discipline in the province.
In order to further absorb high-level talents,the lab is building a talent introduction and management system according to the principle of"setting posts according to needs,selecting and hiring according to posts,classified management and independent cultivation".The lab will soon start a new recruitment process to select a deputy director of scientific research management and nearly 30 senior scientists from all over the world.The recruitment information will be published on its website soon,through which the job applicants can submit their resumes.
In recent years,CDHT's biomedicine industry has developed vigorously and formed a good industrial foundation.It has gathered more than 3,000 pharmaceutical enterprises,such as HitGen,Hinova and AstraZeneca,among which 10 has been listed.It has also founded six national-level platforms,including the largest national safety evaluation center for new drugs and the only national precision medicine industry innovation center in the country.It ranks the third in the comprehensive competitiveness ranking of China's biomedical industrial and research parks in 2022.
According to CDHT,it will take the founding of the lab as an opportunity to further strengthen practical cooperation with universities and institutes,expert teams and leading enterprises to further deepen the research on the frontier and key technologies of biomedicine,further promote the deep integration of innovation chain and industrial chain,and strive to make a number of major original,iconic and leading achievements in the future.In the process,the lab will try and build itself into a source of life and health innovation,and help CDHT to accelerate its construction as a world-leading science and technology park.
党的二十大报告提出，科技是第一生产力、人才是第一资源、创新是第一动力。
为积极抢占全球科技创新制高点，服务国家重大战略需求，支撑成渝地区双城经济圈建设，11月23日，天府锦城实验室（前沿医学中心）在成都高新区正式揭牌运行，这标志着生命健康领域关键核心技术研究迈出了坚实一步，为成渝地区建设具有全国影响力的科技创新中心提供了高能级创新平台支撑。
作为天府实验室的4个方向实验室之一，天府锦城实验室（前沿医学中心）由成都高新区与四川大学等机构联合共建，围绕重大慢病（恶性肿瘤）等人类重大疾病，以临床价值为导向，攻克“卡脖子”技术，着力打通应用基础研究与产业化之间的通道，建立全球领先的全生命周期药械创制体系，实现0-1的突破、1-10的转化和10-N的产业化，全面提升人民健康质量。
业内顶尖院士牵头
聚力攻坚生命健康领域“卡脖子”技术
天府锦城实验室（前沿医学中心）将承担服务大国战略和地方经济两个重大使命，以解决人类临床重大疾病问题的现实需求为目标，聚力攻坚人类生命健康领域“卡脖子”核心关键技术，聚焦原创靶点发现及新药研发、创新医疗器械研发和精准医学等“3+N”研究方向，规划建设从“研究—转化—产业化”的“三极四体系”生态。
其中，原创靶点发现及新药研发方向由魏于全院士牵头，重点聚焦原创靶点发现、靶向药物发现、早期成药性评价和新药CMC研究等研究方向；创新医疗器械研发方向由张兴栋院士牵头，重点聚焦生物医学材料和医疗器械研发、植入器械研发、医用机器人研发和BT+IT医工融合等研究方向；精准医学方向由李为民教授牵头，重点聚焦精准诊断、精准治疗、精准评价和药物精准筛选等研究方向。
此外，实验室将规划建设“三极四体系”生态，充分发挥科技创新优势，吸引全球科研力量参与共建，与产业界合作研发，共同促进技术转移和成果转化，构建开放共享体系。
据成都高新区生物产业局相关负责人介绍，“实验室将以自身科研力量为‘核心承载’，与中国医学科学院、北京大学前沿交叉学院等科研院所共建‘研发基地’，推动重大科研项目和核心技术攻关；联动华大基因、华为公司等头部企业，共建‘转化网格’，形成‘核心+基地+网格’的‘环实验室产业生态’。”
规划超100万㎡创新策源极核
力争跻身世界一流实验室行列
天府锦城实验室（前沿医学中心）核心承载区位于新川片区，毗邻新川TOD，计划投资100亿元形成超100万平方米科技创新策源极核。
实验室分为建成区、在建区和策划区，功能布局已进一步优化。其中，一期已建成29.4万平方米，布局高性能医疗器械、创新药研发等方向，入驻率超95%；二期在建31万平方米，布局医疗大数据智算中心、生物样本库等大科学装置，目前主体结构已全面封顶，拟于2023年交付；三期策划40万平方米，布局疾病动物模型库、精准医学等方向，拟于年底前启动供地。
据悉，成都高新区正研究发布首批次实验室“揭榜挂帅”项目需求清单，将坚持全球首创、同类最优原则进行强链补链布局前沿赛道，重点满足未被满足的临床需求。预期未来3-5年，实验室将建成全球规模最大的生物样本库、国内首个标准化疾病动物模型库、国内最大具有自主核心数据库的AI智算中心等，汇聚一批高端人才，实现10-20个创新药物、15-30个创新医疗器械上市。到2030年，力争跻身世界一流实验室行列。
截至目前，实验室建设成效初步显现。重大科学装置加速布局，已汇聚国家精准医学产业创新中心、国家疾病分子网络等20余个创新服务平台，储备了脑影响引导精神疾病神经调控治疗技术研究等146个项目，成功孵化转化了60余个重点项目。
面向全球招聘近30名资深科学家
加快打造生命健康创新策源地
目前，天府锦城实验室（前沿医学中心）以本领域知名科学家为核心，累计聚集了魏于全院士、张兴栋院士、王广基院士、杨正林院士等领衔的超2000人高水平创新研究团队。实验室合作科学家已在Science、Nature、Cell等全球顶级刊物发表5篇文章，CNS数量占四川省生命科学学科90%以上。
为进一步吸纳高层次人才，实验室将按照“按需设岗、按岗选聘、分类管理、自主培育”的原则构建全方位的人才引育和管理体系。其中，实验室特聘专家拟面向全球按需灵活聘请；全聘人才拟实行全球招聘、编制/员额管理和市场化薪酬；双聘人才拟面向全球选聘、实施项目管理和项目式补贴等。在此基础上，实验室还设置了行政管理岗、科学管理岗、工程技术岗等全方位晋升培养体系。
据悉，实验室将于近期启动相关招聘工作，面向全球遴选1名科研管理副主任、近30名资深科学家等，届时招聘信息可在官方招聘网站查看并投递简历。
近年来，成都高新区生物医药产业发展呈现蓬勃之势，已形成良好的产业基础，聚集了成都先导、海创药业、阿斯利康等医药企业3000余家，累计上市及过会企业10家，全国最大新药安全性评价中心、国内唯一国家精准医学产业创新中心等国家级平台6个，在2022年中国生物医药园区综合竞争力排名中位列第3。
成都高新区相关负责人表示，将以实验室建设为引领，进一步加强与高校院所、专家团队、领军企业的务实合作，进一步深化生物医药前沿及关键技术研究，进一步促进创新链与产业链的深度融合，力争产出一批重大原创性、标志性、引领性成果，努力打造生命健康创新策源地，助力成都高新区加快建设世界领先科技园区。（杜灿）
